GILD Healthcare
Gilead Sciences
| P/E Trailing | 17.19 |
| P/E Forward | 13.08 |
| PEG Ratio | 2.14 |
| Market Cap | $156.86B |
| Price Target | $157.57 (+24.7%) |
| D/E Ratio | 94.64 |
| Current Ratio | 1.97 |
| Cash | $9.82B |
| Total Debt | $22.17B |
| Net Cash | $-12.36B |
| Gross Margin | 79.37% |
| Operating Margin | 39.28% |
| Net Margin | 30.99% |
| ROE | 43.36% |
| FCF | $7.93B |
| GF Score | -- |
| Altman Z-Score | -- |
| Piotroski F-Score | -- |
| Div. Yield | 260.00% |
| Analyst Rating | buy |
HOLD: High leverage - monitor debt levels. Strong profitability with 43.4% ROE. 260.00% dividend yield provides income.
By Karen Roman Imviva Biotech said it has FDA authorization for its Investigational Device Exemption application to use Adaptive Biotechnologies’ clonoSEQ assay in the TENACITY-01 trial to treat leukemia/lymphoma and …
Gilead (GILD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near …
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 12 Most Profitable S&P 500 Stocks to Invest In. On June 25, 2026, the Food and Drug Administration approved Trodelvy from Gilead …
Earlier this week, Gilead Sciences received FDA approval for an expanded use of Trodelvy, authorizing it as a first-line treatment for adults with unresectable locally advanced or metastatic triple-negative breast …
FDA approved Gilead Sciences' (NasdaqGS:GILD) Trodelvy for first line treatment of metastatic triple negative breast cancer in the US. Regulators in Europe granted a similar first line approval, creating aligned …
Ascendis Pharma (ASND) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down …
Gilead Sciences Inc. (NASDAQ:GILD) ranks among the best set-it-and-forget-it stocks to buy right now. Cantor Fitzgerald restated an Overweight rating and a $155 price target for Gilead Sciences Inc. (NASDAQ:GILD) …
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $123.84, denoting a -1.05% move from the preceding trading day.
GILD wins FDA approval to expand Trodelvy into first-line metastatic triple-negative breast cancer, opening a broader treatment opportunity.
Drug companies have found promising new options for one of the most aggressive and hardest-to-treat forms of breast cancer after decades with few breakthroughs. Gilead Sciences won Food and Drug …